• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

105例血管紧张素转换酶抑制剂诱发血管性水肿患者的评估

Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.

作者信息

Rasmussen Eva Rye, von Buchwald Christian, Wadelius Mia, Prasad Sumangali Chandra, Kamaleswaran Shailajah, Ajgeiy Kawa Khaled, Authried Georg, Pallesen Kristine Appel U, Bygum Anette

机构信息

Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, København, Denmark.

Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

出版信息

Int J Otolaryngol. 2017;2017:1476402. doi: 10.1155/2017/1476402. Epub 2017 Feb 14.

DOI:10.1155/2017/1476402
PMID:28286522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5329677/
Abstract

To asses a cohort of 105 consecutive patients with angiotensin converting enzyme-inhibitor induced angioedema with regard to demographics, risk factors, family history of angioedema, hospitalization, airway management, outcome, and use of diagnostic codes used for the condition. Cohort study. . This was a retrospective cohort study of 105 patients with angiotensin converting enzyme-inhibitor induced angioedema in the period 1995-2014. . The cohort consisted of 67 females and 38 males (F : M ratio 1.8), with a mean age of 63 [range 26-86] years. Female gender was associated with a significantly higher risk of angiotensin converting enzyme-inhibitor induced angioedema. 6.7% had a positive family history of angioedema. Diabetes seemed to be a protective factor with regard to angioedema. 95% experienced angioedema of the head and neck. 4.7% needed intubation or tracheostomy. 74 admissions took place during the study period with a total of 143 days spent in the hospital. The diagnosis codes most often used for this condition were "DT783 Quincke's oedema" and "DT78.4 Allergy unspecified". Complement C1 inhibitor was normal in all tested patients. . Female gender predisposes to angiotensin converting enzyme-inhibitor induced angioedema, whereas diabetes seems to be a protective factor.

摘要

评估105例连续的血管紧张素转换酶抑制剂诱导的血管性水肿患者的人口统计学特征、危险因素、血管性水肿家族史、住院情况、气道管理、结局以及用于该疾病的诊断编码的使用情况。队列研究。这是一项对1995年至2014年期间105例血管紧张素转换酶抑制剂诱导的血管性水肿患者的回顾性队列研究。该队列由67名女性和38名男性组成(女性与男性比例为1.8),平均年龄为63岁[范围26 - 86岁]。女性性别与血管紧张素转换酶抑制剂诱导的血管性水肿风险显著较高相关。6.7%有血管性水肿家族史阳性。糖尿病似乎是血管性水肿的一个保护因素。95%经历头颈部血管性水肿。4.7%需要插管或气管切开术。研究期间有74次入院,共住院143天。用于该疾病最常用的诊断编码是“DT783昆克水肿”和“DT78.4未特指的过敏”。所有检测患者的补体C1抑制剂均正常。女性性别易患血管紧张素转换酶抑制剂诱导的血管性水肿,而糖尿病似乎是一个保护因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d88f/5329677/286b66ebd345/IJOTO2017-1476402.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d88f/5329677/286b66ebd345/IJOTO2017-1476402.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d88f/5329677/286b66ebd345/IJOTO2017-1476402.001.jpg

相似文献

1
Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.105例血管紧张素转换酶抑制剂诱发血管性水肿患者的评估
Int J Otolaryngol. 2017;2017:1476402. doi: 10.1155/2017/1476402. Epub 2017 Feb 14.
2
Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor.检测羧肽酶N和补体成分的基线水平,作为血管紧张素转换酶抑制剂相关血管性水肿的潜在预测指标。
Arch Dermatol. 1997 Aug;133(8):972-5.
3
Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema.C1酯酶抑制剂在血管紧张素转换酶抑制剂所致血管性水肿中的作用。
Laryngoscope. 2015 Jun;125(6):E198-202. doi: 10.1002/lary.25113. Epub 2015 Jan 13.
4
Use of C1 Inhibitor for Angiotensin-Converting Enzyme (ACE) Inhibitor-Induced Angioedema Decreases Mechanical Ventilation Time.使用C1抑制剂治疗血管紧张素转换酶(ACE)抑制剂诱发的血管性水肿可缩短机械通气时间。
J Emerg Med. 2015 Dec;49(6):e173-5. doi: 10.1016/j.jemermed.2015.06.076. Epub 2015 Sep 26.
5
Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema.用于治疗严重或危及生命的血管紧张素转换酶抑制剂诱导的血管性水肿的药物的超说明书用药
Ann Pharmacother. 2016 Jan;50(1):47-59. doi: 10.1177/1060028015607037. Epub 2015 Sep 28.
6
Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate.用补体1(C1)抑制剂浓缩物治疗血管紧张素转换酶(ACE)抑制剂引起的血管性水肿。
Acta Anaesthesiol Scand. 2006 Jan;50(1):120-2. doi: 10.1111/j.1399-6576.2005.00819.x.
7
[Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate].[血管紧张素转换酶抑制剂相关血管性水肿:使用补体C1抑制剂浓缩物进行紧急治疗]
Rev Med Interne. 2008 Jun;29(6):516-9. doi: 10.1016/j.revmed.2007.09.038. Epub 2007 Nov 29.
8
Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients.肾素-血管紧张素-醛固酮系统抑制所致血管性水肿的临床特征:84例患者的回顾性分析
J Community Hosp Intern Med Perspect. 2019 Dec 14;9(6):453-459. doi: 10.1080/20009666.2019.1698259. eCollection 2019.
9
Angiotensin Converting Enzyme Inhibitor-related Angioedema: A Case of an Unexpected Death.血管紧张素转换酶抑制剂相关的血管性水肿:一例意外死亡病例
Iran J Allergy Asthma Immunol. 2015 Dec;14(6):642-5.
10
Icatibant in angiotensin-converting enzyme (ACE) inhibitor-associated angioedema.依卡替班治疗血管紧张素转换酶(ACE)抑制剂相关性血管性水肿。
Intern Med J. 2015 Aug;45(8):821-7. doi: 10.1111/imj.12799.

引用本文的文献

1
Non-genetic factors associated with ACE-inhibitor and angiotensin receptor blocker-induced angioedema.与血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂所致血管性水肿相关的非遗传因素。
Clin Transl Allergy. 2025 May;15(5):e70058. doi: 10.1002/clt2.70058.
2
Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema With Resultant Airway Obstruction Following Endotracheal Intubation.血管紧张素转换酶抑制剂诱发的血管性水肿导致气管插管后气道梗阻
Cureus. 2023 Apr 14;15(4):e37594. doi: 10.7759/cureus.37594. eCollection 2023 Apr.
3
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

本文引用的文献

1
Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema.尽管出现血管性水肿,仍继续使用血管紧张素转换酶抑制剂治疗。
Int J Cardiol. 2015 Dec 15;201:644-5. doi: 10.1016/j.ijcard.2015.08.185. Epub 2015 Aug 25.
2
Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors.处方模式的变化作为血管紧张素转换酶抑制剂药物不良反应的潜在标志物。
Int J Clin Pharm. 2015 Dec;37(6):1095-103. doi: 10.1007/s11096-015-0159-3. Epub 2015 Jul 10.
3
A randomized trial of icatibant in ACE-inhibitor-induced angioedema.
国际血管性水肿学会(WAO)/欧洲变态反应和临床免疫学会(EAACI)遗传性血管性水肿管理指南——2021年修订与更新
World Allergy Organ J. 2022 Apr 7;15(3):100627. doi: 10.1016/j.waojou.2022.100627. eCollection 2022 Mar.
4
Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema.外显子组测序揭示 F5 与 ACE 抑制剂和血管紧张素受体阻滞剂诱导血管性水肿相关的常见和罕见变异。
Clin Pharmacol Ther. 2020 Dec;108(6):1195-1202. doi: 10.1002/cpt.1927. Epub 2020 Jul 18.
5
ACE-Inhibitor Related Angioedema Is Not Sufficiently Reported to the Danish Adverse Drug Reactions Database.与血管紧张素转换酶抑制剂相关的血管性水肿未充分上报至丹麦药品不良反应数据库。
Drug Healthc Patient Saf. 2019 Dec 16;11:105-113. doi: 10.2147/DHPS.S205119. eCollection 2019.
6
Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches.血管紧张素转化酶抑制剂诱发血管性水肿的遗传易感性:系统评价和方法学评估。
PLoS One. 2019 Nov 11;14(11):e0224858. doi: 10.1371/journal.pone.0224858. eCollection 2019.
7
Demographic and Clinical Characteristics of Patients Presenting With Angiotensin-converting Enzyme Inhibitors Induced Cough.出现血管紧张素转换酶抑制剂诱导性咳嗽的患者的人口统计学和临床特征
Cureus. 2019 Sep 11;11(9):e5624. doi: 10.7759/cureus.5624.
8
Prescription Pattern of Antihypertensive Drugs: An Experience from a Secondary Care Hospital in the United Arab Emirates.抗高血压药物的处方模式:来自阿联酋一家二级护理医院的经验
J Res Pharm Pract. 2019 Apr-Jun;8(2):92-100. doi: 10.4103/jrpp.JRPP_18_85.
9
Corrigendum to "Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema".《对“105例血管紧张素转换酶抑制剂诱发血管性水肿患者的评估”的勘误》
Int J Otolaryngol. 2018 Mar 1;2018:9169414. doi: 10.1155/2018/9169414. eCollection 2018.
依替巴肽治疗血管性水肿的随机试验。
N Engl J Med. 2015 Jan 29;372(5):418-25. doi: 10.1056/NEJMoa1312524.
4
Angioedema deaths in the United States, 1979-2010.1979 - 2010年美国血管性水肿死亡情况
Ann Allergy Asthma Immunol. 2014 Dec;113(6):630-4. doi: 10.1016/j.anai.2014.09.003. Epub 2014 Oct 3.
5
Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin.与血管紧张素转换酶抑制剂、西他列汀以及3种分解缓激肽的酶缺乏相关的医源性血管性水肿。
Eur Ann Allergy Clin Immunol. 2014 May;46(3):119-22.
6
A consensus parameter for the evaluation and management of angioedema in the emergency department.用于急诊科血管性水肿评估和管理的共识参数。
Acad Emerg Med. 2014 Apr;21(4):469-84. doi: 10.1111/acem.12341.
7
Hereditary angioedema in women: specific challenges.女性遗传性血管性水肿:特殊挑战。
Immunol Allergy Clin North Am. 2013 Nov;33(4):505-11. doi: 10.1016/j.iac.2013.07.006. Epub 2013 Aug 26.
8
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.与血管紧张素转化酶抑制剂相关的血管性水肿相关的遗传变异。
Pharmacogenet Genomics. 2013 Sep;23(9):470-8. doi: 10.1097/FPC.0b013e328363c137.
9
Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel.遗传性血管性水肿伴正常 C1 抑制剂功能:国际专家小组的共识。
Allergy Asthma Proc. 2012 Nov-Dec;33 Suppl 1:S145-56. doi: 10.2500/aap.2012.33.3627.
10
In vivo roles of factor XII.体内因子 XII 的作用。
Blood. 2012 Nov 22;120(22):4296-303. doi: 10.1182/blood-2012-07-292094. Epub 2012 Sep 19.